We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: transthyretin amyloid cardiomyopathy
MedXY News
EnglishTag

transthyretin amyloid cardiomyopathy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy: Toward Mechanism-Specific Monitoring and Therapeutic Response Assessment
Cardiologymechanism-specific therapybiomarker development

Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy: Toward Mechanism-Specific Monitoring and Therapeutic Response Assessment

By MedXY|Aug 13, 2026

This article explores a novel, biologically informed framework for monitoring transthyretin amyloid cardiomyopathy progression and treatment, emphasizing mechanism-specific strategies aimed at personalized care.

Acoramidis Significantly Improves Heart Failure-Related Quality of Life in Transthyretin Amyloid Cardiomyopathy: Insights from the ATTRibute-CM Trial
Cardiology
heart failure
acoramidis

Acoramidis Significantly Improves Heart Failure-Related Quality of Life in Transthyretin Amyloid Cardiomyopathy: Insights from the ATTRibute-CM Trial

By MedXY|Aug 4, 2026

Acoramidis demonstrates substantial benefits in heart failure-related health status among ATTR-CM patients, significantly improving patient-reported outcomes and supporting its role in modifying disease trajectory.

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights
Cardiologyacoramidisalbuminuria

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights

By MedXY|Jul 3, 2026

Acoramidis stabilizes transthyretin and shows kidney-protective effects in transthyretin amyloid cardiomyopathy by reducing eGFR decline and albuminuria, with an initial reversible dip in kidney function associated with improved clinical ou

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy
CardiologyCARDIO-TTRansformcardiovascular outcomes

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy

By MedXY|May 10, 2026

CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen’s efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432

Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months
Cardiologyacoramidistransthyretin amyloid cardiomyopathy

Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months

By MedXY|Nov 18, 2025

In ATTRibute‑CM and its open‑label extension, acoramidis (712 mg twice daily) produced consistent reductions in all‑cause mortality and cardiovascular hospitalizations in both wild‑type and variant ATTR cardiomyopathy, including p.Val142Ile

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities